EMA says ‘no’ to Avandia
24 September, 2010 by David BinningThe European medicines agency announced overnight that it has suspended marketing authorisations for the anti-diabetes medicine Avandia (Rosiglitazone) citing research data linking the drug to increased risk of heart attack and stroke
Mesoblast shareholders approve Angioblast acquisition
23 September, 2010 by David BinningShareholders in regenerative medicine company Mesobast have voted almost unanimously in favour of the company acquiring its US subsidiary Angioblast Systems, increasing its 32.6 percent stake to full ownership.
Wollongong Uni researchers awarded US patent
16 September, 2010 by Staff WritersResearchers from the University of Wollongong’s (UOW) Schools of Chemistry and Health Sciences have been awarded a US patent for their novel method of characterising lipid molecules.
Market report: ASX down slightly despite another rally on Wall Street overnight
10 September, 2010 by David BinningThe Australian Stock Market just managed to stayed ahead for the week this week, as weakness from major sectors pushed down on the market.
Dr Christine Bennett named new chair of Research Australia
03 September, 2010 by Staff WritersResearch Australia today announced the appointment of Dr Christine Bennett as its new chair.
Ramsay reports strong FY profit jump
27 August, 2010 by Staff WritersAustralia’s biggest healthcare provider Ramsay Healthcare this week reported a 21.9 percent jump in full-year net profit to $178.5 million.
Argy-bargy continues at Avexa
27 August, 2010 by David BinningTroubled HIV drug developer Avexa may be poised for yet another coup after major shareholder Caldaza this week called for an extraordinary general meeting to discuss the future of the company
Mesoblast FY results reveal more red ink
26 August, 2010 by David BinningRegenerative medicine specialists Mesoblast today reported a net loss of $14.8 million for the full year ended 30 June 2010, an increase on the previous year’s loss of $12.3 million.
Mesoblast reports FY net loss of $14.8 million
26 August, 2010 by Staff WritersRegenerative medicine specialists Mesoblast today reported a net loss of $14.8 million for the full year ended 30 June 2010. The company, noted, however that it had finished the year with cash reserves of $32.5 million, up from $16.5 million for the previous corresponding period.
Mesoblast to buy US partner Angioblast
24 August, 2010 by Staff WritersRegenerative medicine specialists Mesoblast announced this week that it has convened an extraordinary general meeting with shareholders to vote on the proposed acquisition of the company’s US partner Angioblast Systems.
ALS Exclusive: Senator Kim Carr blasts opposition on science and innovation
20 August, 2010 by David BinningIn an exclusive interview with Australian Life Scientist federal minister for Innovation, Industry, Science and Research Senator Kim Carr has launched a scathing attack on the federal opposition’s lack of vision on science and innovation warning that a victory for Tony Abbott tomorrow would represent a huge backward step for the nation.
Professor Philip Hogg wins lead Eureka prize
20 August, 2010 by Staff WritersProfessor Philip Hogg, Director of the new Lowy Cancer Research Centre at the University of NSW, has received the prestigious 2010 Industry & Investment NSW Eureka Prize for Medical Research Translation.
Monash University professor receives GSK Australia Award for Research
18 August, 2010 by Staff WritersThis year’s prestigious GlaxoSmithKline Australia Award for Research has gone to Monash University’s Professor Charles Mackay for his work on immunology and inflammation, particularly the discovery of GPR43 as a major regulator of innate and inflammatory response.
Monash names Professor Scott O’Neill as new science Dean
13 August, 2010 by David BinningMonash University has announced the appointment of esteemed Australian scientist and medical researcher Professor Scott O’Neill as the University’s new Dean of Science.
Labor science policy has little new for life sciences
11 August, 2010 by Staff WritersThe federal Labor party reached out for the science vote today with the announcement of its Science for Australia’s Future policy, although there’s little there explicitly for life sciences or the biotechnology industry.
